drugset / Trial / NCT01996436

Summary

The primary objective of the study is to determine the optimal intra-arterial drug treatment regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome at 90 days post discharge following optimal intra-arterial drug treatment for cerebral vasospasm. We hypothesize that Intra-arterial (IA) infusion of a combination of multiple vasodilators is more efficacious than single agent treatment cerebral vasospasm therapy. All procedures done as a part of this study are standard hospital care procedures done to treat cerebral vasospasm and all drugs to be used are FDA approved.

Timeline

Start
2016-08-29
Primary completion
2024-04-29
Completion
2024-08-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nicardipine Small molecule 5 mg Other
Comparator Nitroglycerin Unknown 200 ug Other
Comparator Verapamil Other / unclassified 10 mg Other